- Participants will discontinue all asthma medications for the duration of the study including theophylline, LTRAs (montelukast), LABA monotherapy, ipratropium bromide. The design of the study ensures that participants will be on ICS (or ICS+LABA) throughout the study and access to SABA for relief.